The profound effects of sodium-glucose transporter 2 (SGLT2) inhibition on the risks of cardiovascular complications in patients with hyperglycemia have provided for rapid and substantive changes to diabetes guidelines from various countries. In this issue of JAMA, Petrie and colleagues¹ report findings from a highly informative exploratory analysis of the most recent large-scale clinical trial of an SGLT2 inhibitor that may suggest the next chapter for this drug class—the transition from a glucose-lowering therapy that provides cardioprotection to a cardioprotective agent that happens to lower blood glucose.

中文翻译：

---

一种新型的心脏保护疗法，也可以改善血糖。

葡萄糖钠转运蛋白2（SGLT2）抑制对高血糖患者发生心血管并发症的风险产生了深远的影响，这为各国对糖尿病指南的快速，实质性改变提供了条件。在本期JAMA中，Petrie及其同事¹报告了对SGLT2抑制剂的最新大规模临床试验进行的高度有益的探索性分析得出的结论，该发现可能暗示了该药物类别的下一章-从降糖疗法的过渡它为恰好降低血糖的心脏保护剂提供心脏保护。